Latest Articles

Publication Date
Uterine Serous Carcinoma Following the Insertion of Levonorgestrel Int | IJWH - Dove Medical Press

Uterine Serous Carcinoma Following the Insertion of Levonorgestrel Int | IJWH Dove Medical Press

Published: Nov. 4, 2025, 10:26 a.m.
Michelle Wise, MD, discusses levonorgestrel IUD offering effective endometrial protection during hormone therapy - Contemporary OB/GYN

Michelle Wise, MD, discusses levonorgestrel IUD offering effective endometrial protection during hormone therapy Contemporary OB/GYN

Published: Oct. 23, 2025, 8:33 p.m.
Racial and Ethnic Differences in Risk for Hysterectomy Following Insertion of a Levonorgestrel-releasing Intra-uterine device: A Retrospective Cohort Study.

Evidence regarding risk for hysterectomy following treatment for benign gynecological conditions with a Levonorgestrel-releasing intrauterine device (LNG-IUD) is limited. We assess whether race and ethnicity are associated with hysterectomy risk …

Published: July 31, 2025, midnight
Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence.

To investigate the association between the duration of levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer risk in Korean women.

Published: March 13, 2025, midnight
Subdermal implants vs. levonorgestrel intrauterine devices outcomes in reproductive-aged women: a systematic review and meta-analysis.

We aimed to conduct a systematic review and meta-analysis comparing the outcomes of subdermal implants and levonorgestrel intrauterine system (LNG-IUS) in reproductive-aged women.

Published: March 11, 2025, midnight
Women's experience, satisfaction, and continuation with the levonogestrel-containing intrauterine system: A cross-sectional study.

The levonorgestrel-containing intrauterine system (LNG-IUS) is a safe, long-acting, reversible contraceptive method. This study aimed to examine women's experiences, satisfaction, and continuation with the levonorgestrel-containing intrauterine system. This cross-sectional study …

Published: Feb. 20, 2025, 12:15 a.m.
Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS).

Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other …

Published: Jan. 8, 2025, midnight
Cost-effectiveness of long-acting progestogens versus the combined oral contraceptives pill for preventing recurrence of endometriosis-related pain following surgery: an economic evaluation alongside the PRE-EMPT trial.

To evaluate the cost-effectiveness of long-acting progestogens (LAP), including levonorgestrel-releasing intrauterine system (LNG-IUS) and depot-medroxyprogesterone acetate (DMPA), compared with the combined oral contraceptives pill (COCP) in preventing recurrence of endometriosis-related …

Published: Dec. 9, 2024, midnight
Reversal of Endometriosis-Induced Unilateral Ureteral Obstruction and Hydronephrosis With Medical Therapy.

Endometriosis is a common condition among women of reproductive age worldwide, with the urinary tract being the second most frequently affected extragenital organ system, particularly the bladder and ureters. Ureteral …

Published: Nov. 19, 2024, midnight
Continuation of the levonorgestrel-releasing intrauterine device among adolescents with endometriosis.

To estimate the 1-year continuation rate of the levonorgestrel-releasing intrauterine device (LNG-IUD) in adolescents with endometriosis, and the frequency at which additional systemic hormonal treatment (HT) is utilized.

Published: Oct. 25, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!